Begin typing your search above and press return to search.
proflie-avatar
Login
exit_to_app
Can Trump wield his big stick?
access_time 22 Nov 2024 10:39 AM GMT
election commmission
access_time 22 Nov 2024 4:02 AM GMT
Champions Trophy tournament
access_time 21 Nov 2024 5:00 AM GMT
The illness in health care
access_time 20 Nov 2024 5:00 AM GMT
The fire in Manipur should be put out
access_time 21 Nov 2024 9:19 AM GMT
America should also be isolated
access_time 18 Nov 2024 11:57 AM GMT
DEEP READ
Munambam Waqf issue decoded
access_time 16 Nov 2024 5:18 PM GMT
Ukraine
access_time 16 Aug 2023 5:46 AM GMT
Foreign espionage in the UK
access_time 22 Oct 2024 8:38 AM GMT
exit_to_app
Homechevron_rightWorldchevron_rightWHO issues warns...

WHO issues warns against administration of Remdesdivir for Covid-19 treatment

text_fields
bookmark_border
WHO issues warns against administration of Remdesdivir for Covid-19 treatment
cancel
camera_altA health worker collects samples for Covid -19 test from a woman at a market street in Bengalaru City, Image credit: PTI

Geneva: Pointing to the lack of evidence, the World Health Organization (WHO) on Friday warned against the administration of antiviral drug remdesivir on the Covid-19 patients no matter how weak they are as there is no evidence it works.

"The panel found a lack of evidence that remdesivir improved outcomes that matter to patients such as reduced mortality, need for mechanical ventilation, time to clinical improvement, and others," Xinhua news agency quoted the WHO's Guideline Development Group (GDG) panel as saying in a statement.

"Any beneficial effects of remdesivir, if they do exist, are likely to be small and the possibility of important harm remains," the panel added.

The WHO recommendation, published in the British Medical Journal, was based on an evidence review that included data from four international randomised trials among more than 7,000 hospitalised patients.

After reviewing the evidence, the panel concluded that remdesivir has no meaningful effect on death rates or other important outcomes for patients.

"Especially given the costs and resource implications associated with remdesivir... The panel felt the responsibility should be on demonstrating evidence of efficacy, which is not established by the currently available data," it said.

The antiviral is one of only two medicines currently authorized to treat Covid-19 patients across the world.

It has been approval for use in the US, the European Union and other countries after initial research found it may shorten recovery time in some Covid-19 patients.

Made by the US company Gilead, remdesivir is extremely expensive and has to be given intravenously.

Gilead said last month that the drug had boosted its third quarter sales by about $900 million.

The WHO's warning comes as the overall number of global coronavirus cases has topped 56.8 million, while the deaths have surged to more than 1.35 million, according to the Johns Hopkins University.

In its latest update on Friday, the University's Center for Systems Science and Engineering (CSSE) revealed that the current global caseload and death toll stood at 56,817,667 and 1,358,489, respectively.

The US is the worst-hit country with the world's highest number of cases and deaths at 11,710,084 and 252,484, respectively, according to the CSSE.

Show Full Article
TAGS:#Coronavirus#WHO#Covid 19#Remdesivir
Next Story